York, United Kingdom
York, United Kingdom

Time filter

Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-1 | Award Amount: 1.47M | Year: 2011

Regenerative Medicine (use of cells and tissue to replace or heal impaired functions in the body, RM) is one of the fastest growing areas in todays medicine, and has the potential to offer treatment to patients with diseases that are currently untreatable. In many new areas of RM there is however a need to improve the outcome of RM concepts and technologies for it to become a viable option to traditional medicine, or even to motivate the risk of clinical trials and treatments. One of the main problems in several RM areas is that a large portion of the cell and tissue material is lost or made dysfunctional during and shortly after transplantation and that the transplant does not connect to the host tissue as a functional new graft. The specific scientific objective of this project is twofold: 1) to clinically test and prove that Corline Heparin Surfaces (CHS) can be used to protect donated human insulin producing cells that are transplanted to severe cases of Diabetes Type 1 patients, and 2) to broaden the application of the technology and show that the CHS technology can function as a protective and revascularization promoting technology for other Regenerative Medicine areas. The goal is to show CHSs further applicability to Liver Cell therapy, Xeno transplantation of Islet of Langerhans and to Tissue Engineering In addition to the detailed scientific objective, this project has a specific technological objective. The technological objective of this project is to, in partnerships with the participating SMEs, improve European top grade clinical Regenerative Medicine products by combining them with the CHS technology, transferring the application knowledge and integrating the CHS technology into the partners cell and tissue production processes, and to set up a reliable sourcing chain with supply and production of reagents and tissue products to end-user.


News Article | November 22, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Tissue Engineering market is expected to grow from $6.24 billion in 2015 to reach $14.86 billion by 2022 with a CAGR of 13.2%. Growing usage of tissue engineering as an alternative for organs is the major factor propelling the market growth. In addition, recent technological advancements, encouraging government initiatives, and huge investments in R&D are the some of the key factors fostering the market growth. On the other hand, strict regulations for approvals, time taking process to develop a tissue & high costs are the constraints limiting the market growth. Access the complete report at: http://www.strategymrc.com/report/tissue-engineering-market Among all the applications, orthopedic segment leads the market globally with the biggest market share and is expected to grow with a higher CAGR during the forecast period. The growth of this segment is attributed to growing geriatric population and raising incidence of reconstructive and replacement surgeries. Neurology segment is likely to witness faster growth rate due to increasing research & development. North America is emerged as the major revenue generating region in the global market due to innovative technological developments, and increasing incidence of cancer rates in the Canada and U.S. Asia Pacific is expected to witness high growth rate during the forecast period. Some of the key players in global tissue engineering market include Acelity, CryoLife, ReproCell Inc., Stryker Corporation, Medtronic Inc., Integra LifeSciences, RTI Surgical Inc., Acell Inc, Organogenesis Inc, Zimmer Biomet, Athersys Inc, Sanofi, AastromBioSciences, BioMemetic Therapeutics, Tissue Regenix Group Plc, and Advanced Cell Technology. Request for a sample at: http://www.strategymrc.com/report/tissue-engineering-market Applications Covered: • Orthopedics, musculoskeletal and spine • Cardiology & vascular • Neurology • Dental • Cord blood & cell banking • GI & gynecology • Skin/integumentary • Urology • Cancer Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations


Patent
Tissue Regenix | Date: 2014-07-29

The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.


Patent
Tissue Regenix | Date: 2014-07-29

The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.


Trademark
Tissue Regenix | Date: 2014-01-27

(Based on Section 44 (d)) (Based on Section 44 (e)) (Based on Intent to Use) Replacement materials for animal and human tissue, namely, biologic tissues, implants comprising living tissue or comprising biological tissue cultures or comprising processed tissues derived from humans and animals, namely, skin, skin grafts, ureter tissue, bladders, tendons, cartilage, ligaments, blood vessels, nerves, soft tissue for use in the heart and pericardium intended for subsequent implantation; surgical implants comprising living tissue; surgical implants comprising living tissue, namely, vascular patches, meniscus, aortic heart valves, blood vessels, ligaments, cartilage, bone; tissue regeneration materials, namely, human allograft or autograft tissue; Biological implants, namely, a vital processed human or animal connective tissue, namely, xenograft tissue; biological implants for guided tissue regeneration, namely, a vital processed human or animal connective tissue; arterial vascular grafts; human allograft tissue formed for use as a surgical patch; Biological implants, namely, a vital processed human or animal connective tissue, namely, heart valve implants comprising human or animal tissues; small diameter skin grafts. (Based on Section 44 (d)) (Based on Section 44 (e)) (Based on Intent to Use) Surgical implants comprising textile material to encourage the growth of tissue, namely, medical, surgical and orthopaedics implants made of artificial textile materials; surgical implants and mesh made of synthetic materials for use in soft tissue; surgical and intravascular implants comprised of artificial textile material. (Based on Section 44 (d)) (Based on Section 44 (e)) Treatment of materials, namely, treatment of living cells and tissue, namely, removing immunogenic materials. (Based on Section 44 (d)) (Based on Section 44 (e)) (Based on Intent to Use) Medical research and scientific research in the field of replacement tissues for humans and animals, regenerative medical devices.


Trademark
Tissue Regenix | Date: 2014-06-06

Replacement materials for animal and human tissue, namely, biological tissues, namely, skin, skin grafts, ureter tissue, bladders, tendons, cartilage, ligaments, blood vessels, nerves, soft tissue for use in the heart and pericardium intended for subsequent implantation; surgical implants comprising living tissue; surgical implants comprising living tissue, namely, vascular patches, meniscus, aortic heart valves, blood vessels, ligaments, cartilage, bone; tissue regeneration materials, namely, human allograft or autograft tissue; Biological implants, namely, a vital processed human or animal connective tissue, namely, xenograft tissue; biological implants for guided tissue regeneration, namely, a vital processed human or animal connective tissue; arterial grafts; human allograft tissue formed for use as a surgical patch; Biological implants, namely, a vital processed human or animal connective tissue, namely, heart valve implants comprising human or animal tissues; small diameter skin grafts. Surgical implants comprising artificial tissue, namely, non-living surgical implants originally derived from humans and animals intended for subsequent implantation comprising bone, skin, skin grafts, ureters, bladders, tendons, cartilage, ligaments, blood vessels, nerves, soft tissue for use in the heart and pericardium; surgical implants comprising textile material to encourage the growth of tissue, namely, medical, surgical and orthopaedics implants made of artificial textile materials; surgical implants and mesh made of synthetic materials for use in soft tissue; surgical and intravascular implants comprised of artificial textile material. Medical research and scientific research in the field of replacement tissues for humans and animals, regenerative medical devices; treatment of living cells and tissue, namely, removing immunogenic materials.


Trademark
Tissue Regenix | Date: 2014-09-23

Replacement materials for animal and human tissue, namely, biological tissues, namely, skin, skin grafts, tendons, ligaments; surgical implants comprising living tissue; surgical implants comprising living tissue, namely, ligaments; tissue regeneration materials; biological implants, namely, a vital processed animal connective tissue, namely, xenograft tissue; biological implants for guided tissue regeneration, namely, a vital processed human or animal connective tissue; human allograft tissue formed for use as a surgical patch; biological implants, namely, a vital processed human or animal connective tissue; small diameter skin grafts. Surgical implants comprising artificial tissue, namely, non-living surgical implants originally derived from animals intended for subsequent implantation comprising skin, skin grafts. Medical research and scientific research in the field of replacement tissues for humans and animals, regenerative medical devices; treatment of living cells and tissue, namely, removing immunogenic materials.


News Article | February 23, 2017
Site: www.businesswire.com

SAN ANTONIO--(BUSINESS WIRE)--Tissue Regenix, the U.K.-based leader in regenerative medicine, has established its decellularization (dCELL®) Technology in wound care in the United States with plans to expand into other medical sectors. The company has opened up new possibilities in regenerative medicine in the U.K., applying its dCELL® Technology to several therapeutic applications. The company launched U.S. operations through their chronic and acute wound care product, DermaPure®, and will progress into other applications, including orthopedics in early 2018. The patented dCELL® Technology is a multi-tissue regenerative medical platform which can be used in a wide range of medical applications to allow the body to regenerate critical tissue through utilizing decellularized animal and human biological materials. DNA and other cellular material are removed from the tissue, leaving the acellular scaffold intact. dCELL® Technology provides support for cell migration during the healing process all while preserving necessary tissue strength. It avoids rejection by the patient’s body and integrates into the host tissue without the use of harsh chemicals or treatments. “We have seen first-hand how life changing these products have been in Europe, and we are thrilled to bring our dCELL® Technology to the United States to help a new population of patients heal faster and more effectively,” said Antony Odell, CEO of Tissue Regenix. “These solutions are bringing hope to people who have conditions that may otherwise be beyond repair.” DermaPure®, the decellularized human dermis product from Tissue Regenix, is currently available in the U.S. for patients with hard-to-heal acute and chronic wounds. DermaPure is produced from donated human tissue and it is 99% DNA free. This minimal DNA content closely mimics the structure and function of the native tissue it is replacing. It signals a bio-normal response by not eliminating but reducing inflammation, and stimulates the body to progress through the phases of natural wound healing. Wounds can be healed with as little as one use, potentially providing patients with faster healing and delivering a quicker recovery. Tissue Regenix is currently undertaking clinical trials in the EU and will look to introduce dCELL® Technology to orthopedic applications in the U.S. in 2018, initially addressing ACL repair. They will be attending the American Academy of Orthopedic Surgeons (AAOS) annual meeting in March to share more information on this progress with a team of orthopedic and sports medicine experts. Members of Tissue Regenix’s clinical advisory board will attend AAOS, including: “The application of dCELL® Technology in orthopedics will give surgeons and clinicians an innovative new way to provide care to patients requiring anterior cruciate ligament (ACL) reconstruction, meniscus replacement and other injuries,” said Drew Distin, VP of Orthopedics at Tissue Regenix. Tissue Regenix will be exhibiting at booth #5750 at the American Academy of Orthopedic Surgeons meeting in San Diego, CA March 14-17. Tissue Regenix was founded in the U.K. in 2006 to develop and commercialize decellularization research from the University of Leeds and listed on the London Stock Exchange in 2010. With U.S. headquarters in San Antonio, TX, the company continues to develop its roster of products using this technology. For more information about Tissue Regenix, please visit http://www.tissueregenix.com/. About Tissue Regenix Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularization ('dCELL®') Technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.


SAN ANTONIO, Texas--(BUSINESS WIRE)--Tissue Regenix Wound Care, Inc., today announced the company has been awarded a group purchasing contract with Premier Inc., a leading healthcare improvement company, for Breakthrough Technology: Bone Tissue Synthetic Implantable Products. The agreement provides Premier members with access to DermaPure® human dermal allograft featuring dCELL® technology for the treatment of complex, acute and chronic wounds. Antony Odell, CEO, Tissue Regenix Group plc commented: “Approval by Premier marks a significant step for DermaPure®. This confirms the unique characteristics of our patented dCELL® technology, the powerful clinical evidence we have collected and the remarkable outcomes it achieves in real world clinical situations.” Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World. In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform. Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of approximately 3,600 U.S. hospitals and 120,000 other providers. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram, Foursquare and Premier’s blog for more information about the company.

Loading Tissue Regenix collaborators
Loading Tissue Regenix collaborators